ADPT | tickerfilter.com

Fundamental analysis

35%

Profitability 35%

Dept financing 15%

Liquidity 75%

Performance 31%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

7.05%

1 Month

3.00%

3 Months

0.64%

6 Months

69.16%

1 Year

187.27%

2 Year

10.64%

Key data

Stock price

$7.90

P/E Ratio

0.00

DAY RANGE

$7.68 - $7.96

EPS

-$1.08

52 WEEK RANGE

$2.56 - $9.01

52 WEEK CHANGE

$187.27

MARKET CAP

884.739 M

YIELD

N/A

SHARES OUTSTANDING

147.472 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-01-2025

BETA

1.57

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,008,142

AVERAGE 30 VOLUME

$2,317,207

Company detail

CEO: Chad Robins
Region: US
Website: adaptivebiotech.com
Employees: 790
IPO year: 2019

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals. It serves the life sciences research, clinical diagnostics, and drug discovery applications.

ADPT - Adaptive Biotechnologies Corp